Management of patients undergoing hydroxychloroquine (Plaquenil) therapy

Clinical and Experimental Optometry

Volumn 83, Issue 1, 2000, Pages 32-36

  Weisinger, Harrison S ^a   Pesudovs, Konrad ^b   Coffin, H Barry ^c  

^a RMIT UNIVERSITY   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bull s eye maculopathy; Corneal verticillata; Hydroxychloroquine; Plaquenil; Quinoline toxicity; Retinopathy

Indexed keywords

EID: 30344486898     PISSN: 08164622     EISSN: 14440938     Source Type: Journal    
DOI: 10.1111/j.1444-0938.2000.tb05072.x     Document Type: Article

References (47)

1. HERA A randomized trial of chloroquine in early rheumatoid arthritis: the HERA study. Am J Med 1995; 98: 156–168.
2. Silman A., Shipley M. Ophthalmological monitoring for hydroxychloroquine toxic-ity: a scientific review of available data. Br J Rheumatol 1997; 36: 599–601.
3. Fielder A., Graham E., Jones S., Silman A., Tullo A. Royal College of Ophthalmologists guidelines: Ocular toxicity and hydroxychloroquine. Eye 1998; 12: 907–909.
4. Tokumaru GK. New considerations in monitoring for hydroxychloroquine retinopathy. Clin Eye Vis Care 1996; 8: 99–104.
5. Hobbs HE, Calnan CD. The ocular complications of chloroquine therapy. Lancet 1958; 1: 1207–1208.
6. Hobbs HE, Sorsby A., Freeman A. Retinopathy following chloroquine therapy. Lancet 1959; 2: 478–479.
7. Hobbs HE, Eadie SP, Somerville F. Ocular lesions after treatment with chloroquine. Br J Ophthalmol 1961; 45: 284–297.
8. Collin HB. Ocular complications of chloroquine therapy. Aust J Optom 1962; 45: 322–325.
9. Aylward JM. Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity. J Am Optom Assoc 1993; 64: 787–797.
10. Schachat AP, Murphy RB, Patz A. Medical Retina. In: Ryan SJ ed. Retina. Vol 2, St Louis: The CV Mosby Company: 1989: 742–744.
11. Michaelson IC. Retinal degenerations. In: Michaelson IC ed. Textbook of the Fundus of the Eye. Edinburgh: Churchill Livingstone, 1980: 406–434.
12. Maturi RK, Folk JC, Nichols B., Oetting TT, Kardon RH. Hydroxychloroquine retinopa-thy. Arch Ophthalmol 1999; 117: 1262–1263.
13. Thome JE, Maguire AM. Retinopathy after long term, standard doses of hydroxychloroquine. Br J Ophthalmol 1999; 83: 1201–1202.
14. Bernstein HN. Ocular safety of hydroxychloroquine sulfate (Plaquenil). Southern Med J 1992; 85: 274–279.
15. Fuld H. Retinopathy following chloroquine therapy. Lancet 1959; 2: 617–619.
16. Wilson W. Retinopathy during chloroquine therapy. Br J Ophthalmol 1961; 45: 756–758.
17. Hobbs HE. Eye changes with chloroquine. BMJ 1966; 1: 1109–1115.
18. Easterbrook M. Long-term course of anti-malarial maculopathy after cessation of treatment. Can J Ophthalmol 1992; 27: 237–239.
19. Easterbrook M. The long-term safety of hydroxychloroquine. Sent Arthritis Rheum 1993; 23: 62–67.
20. Okun E., Gouras P., Bernstein HN, von Sallmann L. Chloroquine retinopathy: a report of eight cases with ERG and dark adaption findings. Arch Ophthalmol 1963; 69: 59–71.
21. Hart WMJ, Burde RM, Johnston GP, Drews RC. Static perimetry in chloroquine retinopathy: perifoveal patterns of visual field depression. Arch Ophthalmol 1984; 102: 377–380.
22. Hansen E. Chloroquine retinopathy evaluated with colour perimetry. Ann Ther Clin Ophthalmol 1974; 25: 323–331.
23. Shearer RV, Dubois EL. Ocular changes induced by long-term hydroxychloroquine (Plaquenil) therapy. Am J Ophthalmol 1967; 64: 245–252.
24. Rebello DJA. Ocular reactions to anti-malarial drugs. Arch Derm 1961; 83: 785–789.
25. Vinals AF, Kenyon KR. Corneal manifestations of metabolic diseases. Int Ophthalmol Clin 1998; 38: 141–153.
26. Collin HB, Penry VF. The ocular manifestations of Fabry’s disease: A family study. Aust J Optom 1983; 66: 173–177.
27. Biard L., Perdriel G., Chevaleraud J., Vignat J-P. Diagnostic problems in chloroquine central retinopathy. Bul Soc Ophthalmol Fr 1973; 73: 539–544.
28. Hobbs HE, Calnan CD. Visual disturbances with antimalarial drugs with particular reference to chloroquine keratopathy. Arch Dermatol 1959; 80: 557–563.
29. Kaswell A. MIMS Annual. 22nd Australian ed. Singapore: Tien Wah Press, 1998.
30. Mayer W. Chloroquine retinopathy. Am J Ophthalmol 1962; 53: 769–774.
31. Dall JLC, Keane JA. Disturbances of pigmentation with chloroquine. BMJ 1959; 1387–1389.
32. Brinkley JR, Dubois EL, Ryan SJ. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol 1979; 88: 1–11.
33. Crews SJ, Cantab MB. Chloroquine retinopathy with recovery in early stages. Lancet 1964; 2: 436–438.
34. Burns RP. Delayed chloroquine retinopathy. N Eng J Med 1966; 275: 693–696.
35. Bernstein HN, Zvaifler N., Rubin M., Mansour AM. Ocular deposition of chloroquine. Invest Ophthalmol Vis Sci 1963; 2: 384–392.
36. Meier-Ruge W. Experimental investigation of the morphogenesis of chloroquine retinopathy. Arch Ophthalmol 1965; 73: 540–544.
37. Yanoff M., Tsou K-C. A tetrazolium study of the whole eye. Effect of chloroquine in the incubation medium. Am J Ophthalmol 1965; 59: 808–810.
38. Rynes RI, Krohel G., Falbo A., Reinecke RD, Wolfe B., Bartholomew LE. Ophthalmologi-cal safety of long-term hydroxychloroquine treatment. Arthritis Rheum 1979; 22: 832–836.
39. Tobin DR, Krohel GB, Rynes RI. Hydroxychloroquine—seven year experience. Arch Ophthalmol 1982; 100: 81–83.
40. Mantyjarvi M. Hydroxychloroquine treatment and the eye. Scand J Rheumatol 1985; 14: 171–174.
41. Morsman CDG, Livesey SJ, Richards IM, Jessop JD, Mills PV. Screening for hydroxychloroquine retinal toxicity. Is it necessary Eye 1990; 4: 572–576.
42. Arden GB, Kolb H. Antimalarial therapy and early retinal change in patients with rheumatoid arthritis. BMJ 1966; 1: 270–273.
43. Nylander U. Ocular damage in chloroquine therapy. Acta Ophthalmol 1996; 44: 335–347.
44. Levy GD, Munz SJ, Paschal J., Cohen HB, Pince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicentre outpatient practice. Arthritis Rheum 1997; 40: 1482–1486.
45. Mavrikakis M., Papazoglou S., Sfikakis PP, Vaiopoulos G., Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996; 55: 187–189.
46. Mills PV, Beck M., Power BJ. Assessment of the retinal toxicity of hydroxychloroquine. Trans Ophthalmol Soc UK 1981; 101: 109–113.
47. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987; 104: 139–144.